Even in the case of uncomplicated infections, the body prepares itself early on for the possibility of a more severe course. A research team from the Technical University of Munich (TUM) and Helmholtz ...

Recent innovations include engineering CAR T-cells to overcome the immunosuppressive tumour microenvironment and enhancing ...

The Lancet Respiratory Medicine published a phase 2 clinical study article on China's first DPP-1 inhibitor, HSK31858, led by ...

This study provides proof-of-principle data for the use of trained immunity to modulate macrophage interactions with tumours. The study makes a valuable contribution to the field of trained immunity.

Researchers at the FAMU-FSU College of Engineering have developed a novel method for investigating protein degradation in immune cells.

FAMU-FSU College of Engineering researchers have created a new method for studying protein degradation within immune cells ...

The telogen phase of the hair cycle is just one part of a much larger process. You may not realize that the hair on your head, arms, face, and everywhere else on your body is constantly passing ...

MONTREAL, March 26, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight"), a pan-American (ex-US) specialty pharmaceutical company, announced today the launch of Minjuvi ® ...

MONTREAL, March 26, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight"), a pan-American (ex-US) specialty pharmaceutical company, announced today the launch of Minjuvi ...

Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced an abstract on AFM24 dose optimization ...

DR-0201 is a potential first-in-class CD20-directed bispecific antibody that targets and engages specific tissue-resident and trafficking myeloid cells to induce deep B-cell depletion via targeted ...